Fig. 2: Origin of the variants detected by liquid biopsy test. | British Journal of Cancer

Fig. 2: Origin of the variants detected by liquid biopsy test.

From: Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy

Fig. 2

By comparing the results obtained by the liquid biopsy panel to those from the other genomic panels, the origin of most of the identified variants was clarified. 29.1% (25/86) of the variants have germline origin (blue), 38.4% (33/86) were derived from clonal haematopoiesis (red), and the remaining 32.6% (28/86) were considered real ctDNA variants, potentially derived from the tumour (yellow). Regarding those tumour ctDNA variants, 17 were present in the tissue biopsy (60.7% of ctDNA variants, 19.8% of total) and 11 were not (39.3% of ctDNA variants, 12.8% of total). Of those absent in the tissue biopsy, other 5 variants were assumed to derive from the tumour in the light of serial liquid biopsies results (17.9% of ctDNA variants, 5.8% of total) whereas the suspected tumour origin of the other 6 (21.4% of ctDNA variants, 7.0% of total) could not be ascertained.

Back to article page